Although a clear positive effect of anti-TNFα and anti-IL-6R treatment of RA has been demonstrated in a number of clinical trials (Nam et al., 2017[26]), the therapeutic intervention into the significant hematopoietic pathways regulated by TNFα or IL-6 can result in serious hematological abnormalities. The gene discussed is TNF; the disease is rheumatoid arthritis.